|Videos|May 4, 2022
Urology Times 50 Innovations Series: Microsurgical testicular sperm extraction
Author(s)Urology Times staff
"Micro TESE is associated with higher sperm retrieval rates compared with conventional testicular sperm extraction, so this approach has really become the gold standard for sperm extraction in patients with non-obstructive azoospermia," says Denise Asafu-Adjei, MD, MPH.
Advertisement
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Denise Asafu-Adjei, MD, MPH, discusses the development of microsurgical testicular sperm extraction (microTESE). Asafu-Adjei is a urologist and medical director of male reproductive medicine at Loyola University, Chicago, Illinois.
Advertisement
Related to this article
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Advertisement
Advertisement
Trending on Urology Times
1
The Evolving Landscape of Minimally Invasive BPH Therapy
2
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
3
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
4
AACU, WOCN Society urge safeguards in Medicare catheter bidding
5